

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2500.142US2

SERIAL NO.

09/315,574

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary) JAN 0 / 2001

APPLICANT

JAMES D. MARKS et al.

FILED

May 20, 1999

GROUP

1643

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
H.S.	A1 5 1 6 9 7 7 4	12/72	Frankel et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)
H.S. B1 92 / 2 2 6 5 3	12/92	PCT			Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

H.S.	C1	Huston, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ", Proceedings of the National Academy of Sciences, Vol. 85, August 1988, pp. 5879-5883.
	C2	Vallera Daniel A., "Immunotoxins: Will Their Clinical Promise be Fulfilled", Blood: The Journal of The American Society of Hematology, Vol. 83, No. 2, January 15, 1994, pp. 309-317.
	C3	Trail, et al., "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates", Science, July 9, 1993, Vol. 261, pp. 212-215.
	C4	Weiner, et al., Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin a Chain Immunoconjugate", Cancer Research, Vol. 49, July 15, 1989, pp. 4062-4067.
	C5	Riethmuller, et al., "Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers", Current Opinion in Immunology, 1992, Vol. 4, pp. 647-655.
	C6	Brinkmann, et al., "A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of <i>Pseudomonas</i> exotoxin", Proceedings of the National Academy of Sciences, January 1993, Vol. 90, pp. 547-551.
	C7	Colcher, et al., "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies", Cancer Research, August 15, 1988, Vol. 48, pp. 4597-4603.
H.S.	C8	Gallinger, et al., "Comparative Dual Label Study of First and Second Generation Antitumor-associated Glycoprotein-72 Monoclonal Antibodies in Colorectal Cancer Patients", Cancer Research, January 15, 1993, Vol. 53, pp. 273-278.

EXAMINER

Hong Sang

DATE CONSIDERED

9/1/2005

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JAN 08 2003

TECH CENTER 1600/2900

FORM PT01449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2500.142US2		SERIAL NO. 09/315,574	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT JAMES D. MARKS et al.			
				FILED May 20, 1999		GROUP 1643	
U. S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)							
H.S.	C9	Adams, et al., "Highly Specific <i>in Vivo</i> Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-cerbB-2 Single Chain Fv.					
	C10	Hoogenboom, et al., "Building Antibodies from their Genes", Immunological Reviews, 1992, No. 130, pp. 41-68.					
	C11	Marks, et al., "By-passing Immunization Human: Human antibodies from V-gene Libraries Displayed on Phage", Journal of Mol. Biology, 1991, Vol. 222, pp. 581-597.					
	C12	Marks, et al., "By-passing Immunization Human: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, July 1992, Vol. 10., pp. 779-783.					
	C13	Hawkins, et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation", Journal of Mol. Biology, 1992, Vol. 226, pp. 889-896.					
	C14	Reichmann, et al., "Phage Display and Selection of a Site-Directed Randomized Single-Chain Antibody Fv Fragment for Its Affinity Improvement", Biochemistry, 1993, Vol. 32, pp. 8848-8855.					
	C15	McCafferty, et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, December 6, 1990, Vol. 348, pp. 552-554.					
	C16	Griffiths, et al., "Human anti-self antibodies with high specificity from phage display libraries", EMBO Journal, 1993, Vol. 12, No. 2, pp. 725-734.					
	C17	Clackson, et al., "Making antibody fragments using phage display libraries", Nature, August 15, 1991, Vol. 352, pp. 624-628.					
	C18	Group, E.B.C.T.C., "Systemic Treatment of Early Breast Cancer by Hormonal Cytotoxic, or immune therapy, Lancet, 1992, Vol. 339, pp. 1-15.					
H.S.	C19	Allred, et al., "Overexpression of HER-2/neu and its Relationship with other prognostic factors change during the progression of <i>in situ</i> to invasive breast cancer", Human Pathology, September 1992, Vol. 23, No. 9, pp. 974-979.					
EXAMINER				DATE CONSIDERED			
Hong sang				9/1/05			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED

JAN 08 2003

TELETYPE UNIT 1600:2900

FORM PT01449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2500.142US2		SERIAL NO. 09/315,574	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANT JAMES D. MARKS et al.			
				FILED May 20, 1999		GROUP 1643	
U. S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent pages, Etc.)</i>							
H.S.	C20	Slamon, et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene", Science, January 9, 1987, Vol. 235, pp. 177-182.					
	C21	Carter, et al., "Towards an immunotherapy for p185HER2 overexpressing tumors", Antigen & Antibody Engineering in Breast Cancer Diagnosis, 1994, pp. 83-94.					
	C22	Shepard, et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogenic to the Clinic", Journal of Clinical Immunology, 1991, Vol. 11, No. 3, pp. 117-127.					
	C23	Soderlind, et al., "Phage Display Technology in Antibody Engineering: Design of Phagemid Vectors and <i>in vitro</i> Maturation Systems", Immunological Reviews, 1992, No. 130, pp. 109-124.					
	C24	Borrebaeck Carl A.K., "Strategy for the production of human monoclonal antibodies using in vitro activated B cells", Journal of Immunological Methods, Vol. 123, 1989, pp. 157-165.					
H.S.	C25	Disis, et al., "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer", Cancer Research, Vol. 54, January 1, 1994, pp. 16-20.					
EXAMINER				DATE CONSIDERED			
<i>Henry Sang</i>				<i>9/11/05</i>			
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

RECEIVED

JAN 13 2003

TECH CENTER 1600/2900